Brixadi (buprenorphine) is a prescription drug that’s used to treat opioid use disorder (OUD). Brixadi comes as a liquid solution in a prefilled syringe. You’ll receive Brixadi as an injection under ...

Braeburn Inc. today announced the presentation of three posters at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting in Miami, FL, adding to the growing body of clinical and ...

Please provide your email address to receive an email when new articles are posted on . The FDA tentatively approved certain Brixadi injections for treatment of moderate to severe opioid use disorder, ...

EYEWITNESS NEWS (WBRE/WYOU) — The U.S. Food and Drug Administration (FDA) approved a Buprenorphine treatment option for opioid addiction. According to the FDA, Brixadi is an extended-release injection ...

Please provide your email address to receive an email when new articles are posted on . Brixadi is the first long-acting buprenorphine injectable that is available in weekly and monthly doses.

Brixadi is the first treatment for opioid use disorder in the US with both weekly and monthly dosing Three million people in the US diagnosed with opioid use disorder LUND, Sweden, May 24, 2023 ...

Credit: Braeburn. Brixadi (weekly) and Brixadi (monthly) are different formulations. Brixadi ® (buprenorphine) extended-release subcutaneous injection is now available for the treatment of moderate to ...

LUND, Sweden, Dec. 23, 2018 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) announced today that the US Food and Drug Administration (FDA) has issued Camurus' US partner Braeburn a tentative approval of ...

BRIXADI is now available for healthcare settings and pharmacies through a restricted distribution program called the BRIXADI REMS and is administered only by a healthcare professional. PLYMOUTH ...

Brixadi (buprenorphine) is a brand-name injection that’s prescribed for opioid use disorder. As with other drugs, Brixadi can cause side effects, such as injection site reactions and respiratory ...